---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125351"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:59:18.551562+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences reports Q3 loss $20.3M; halts PALIZADE LN trial over fatal SAEs

## Summary
- Net loss $20.3M ($2.78/share) vs $23.1M ($3.18) in Q3 2023; cash, equivalents and marketable securities $148.4M (Dec 31: $201.4M).
- Terminated PALIZADE Phase 2b lupus nephritis trial after 4 fatal serious adverse events; full clinical hold by FDA.
- PORTOLA autoimmune hepatitis trial: topline data expected H1 2025; IDMC recommended continue; FDA partial hold on open-label extension.
- Completed 1-for-10 reverse stock split on Oct 29, 2024 to regain $1.00 minimum bid compliance on Nasdaq.
- R&D expenses decreased to $16.2M from $23.7M; G&A to $5.7M from $8.8M due to strategic restructuring.

## SEC filing metadata
- accession: 0000950170-24-125351
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017024125351/0000950170-24-125351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017024125351/kzr-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125351
- JSON: https://secwatch.observer/filing/0000950170-24-125351.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125351.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.